Anbio Biotechnology Class A Ordinary Shares (NNNN) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Anbio Biotechnology Class A Ordinary Shares (NNNN) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry, with a market capitalization near $1.44B, listed on NASDAQ, employing roughly 27 people, carrying a beta of 4.66 to the broader market. Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. Led by Michael Lau, public since 2025-02-19.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for NNNN as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.